CoChat
Sign Up
Cited by 46

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Transgenic mice expressing APP-C100 in the brain.

Neve, Rachael L., Boyce, Frederick M., McPhie, Donna L., Greenan, Jane, Oster-Granite, Mary Lou·1996·Neurobiology of Aging
DOI 10.1016/0197-4580(95)02074-8
Open this paper in CoChat — free account

Abstract

The classic hallmarks of Alzheimer's disease are the deposition of amyloid in plaques and in the cerebrovasculature, and the emergence of neurofibrillary tangles in neurons. The interplay between these two pathologic processes, on the one hand, and the degeneration of neurons and loss of cognitive functions on the other, remains incompletely understood. We have proposed that one crucial component of this interplay is a fragment of the Alzheimer amyloid protein precursor (APP) comprising the carboxyterminal 100 amino acids of this molecule, which we term APP-C100 (or, more simply, C100). This fragment, which comprises the 42-amino acid amyloid protein (A beta) and an additional 58 amino acids carboxyterminal to it, was found to be toxic specifically to nerve cells in vitro. We developed transgenic mouse models to test the hypothesis that APP-C100 causes Alzheimer's disease neuropathology. APP-C100 was delivered to the mouse brain via a transgene expressing C100 under the control of the dystrophin brain promoter. These transgenic animal models for the action of APP-C100 in the brain exhibited some of the neuropathological features characteristic of Alzheimer disease brain. The animal models that we have created can be used to test hypotheses concerning the mechanism by which C100 interacts with a neuronal receptor to kill neurons.

Overview

Integrity signals

Registry

Crossref · 10.1016/0197-4580(95)02074-8

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 33

  1. Benowitz, 1989, The amyloid precursor protein is concentrated in neuronal lysosomes in normal and Alzheimer disease subjects, Exp. Neurol., 106, 237, 10.1016/0014-4886(89)90156-8 · DOI
  2. Cummings, 1992, Aggregation of the amyloid precursor protein within degenerating neurons and dystrophic neurites in Alzheimer's disease, Neuroscience, 48, 763, 10.1016/0306-4522(92)90265-4 · DOI · Paper page
  3. Davies, 1992, Alz-50 as a reagent to assess animal models of Alzheimer's disease, Neurobiol. Aging, 13, 613, 10.1016/0197-4580(92)90066-7 · DOI
  4. DeKosky, 1990, Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity, Ann. Neurol., 27, 457, 10.1002/ana.410270502 · DOI · Paper page
  5. Frautschy, 1992, Phagocytosis and deposition of vascular β-amyloid in rat brains injected with Alzheimer β-amy-loid, Am. J. Pathol., 140, 1389
  6. Fukuchi, 1992, Overexpression of amyloid precursor protein alters its normal processing and is associated with neurotoxicity, Biochem. Biophys. Res. Commun., 182, 165, 10.1016/S0006-291X(05)80126-3 · DOI
  7. Fukuchi, 1993, Selective neurotoxicity of COOH-terminal fragments of the β-amyloid precursor protein, Neurosci. Lett., 154, 145, 10.1016/0304-3940(93)90192-N · DOI
  8. Fukuchi, 1994, Overexpression of a Cterminal portion of the β-amyloid precursor protein in mouse brains by transplantation of transformed neuronal cells, Exp. Neurol., 127, 253, 10.1006/exnr.1994.1101 · DOI
  9. Games, 1995, Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein, Nature, 373, 523, 10.1038/373523a0 · DOI · Paper page
  10. Hamos, 1989, Synaptic loss in Alzheimer's disease and other dementias, Neurology, 39, 355, 10.1212/WNL.39.3.355 · DOI · Paper page
  11. Kosik, 1992, Is β-amyloid neurotoxic?, Neurobiol. Aging, 13, 535, 10.1016/0197-4580(92)90052-Y · DOI
  12. Kozlowski, 1992, The neurotoxic carboxyterminal fragment of the Alzheimer amyloid precursor binds specifically to a neuronal cell surface molecule: pH dependence of the neurotoxicity and the binding, J. Neurosci., 12, 1679, 10.1523/JNEUROSCI.12-05-01679.1992 · DOI
  13. Liberini, 1993, Alz-50 immunoreactivity in the central nervous system of adult rat and primate, Neurosci. Lett., 151, 200, 10.1016/0304-3940(93)90020-L · DOI
  14. Mann, 1974, The quantitative assessment of lipofuscin pigment, cytoplasmic INA and nucleolar volume in senile dementia, Neuropathol. Appl. Neurobiol., 4, 129, 10.1111/j.1365-2990.1978.tb00553.x · DOI
  15. Martin, 1994, Synaptic pathology and glial responses to neuronal injury precede the formation of senile plaques and amyloid deposits in the aging cerebral cortex, Am. J. Pathol., 145, 1358
  16. Martin, 1991, Cells transfected with amyloid precursor protein DNA fragment AB-1 produce medium toxic to differentiated PC12 cells, Soc. Neurosci. Abstr., 17, 1072
  17. Maruyama, 1990, Formation of amyloid-like fibrils in COS cells overexpressing part of the Alzheimer amyloid protein precursor, Nature, 347, 566, 10.1038/347566a0 · DOI
  18. Mullan, 1993, Genetic and molecular advances in Alzheimer's disease, Trends Neurosci., 16, 398, 10.1016/0166-2236(93)90007-9 · DOI
  19. Neve, 1988, Expression of the Alzheimer amyloid precursor gene transcripts in the human brain, Neuron, 1, 669, 10.1016/0896-6273(88)90166-3 · DOI
  20. Neve, R. L.; Boyce F. M. In: Perez-Polo, J. R., ed. Paradigms of Neural Injury Construction and analysis of transgenic mice expressing amyloidogenic fragments of the Alzheimer amyloid protein precursor. Methods Neurosci. (in press).
  21. Nitta, 1994, β-Amyloid proteininduced Alzheimer's disease animal model, Neurosci. Lett., 170, 63, 10.1016/0304-3940(94)90239-9 · DOI
  22. Oster-Granite, 1992, Structural alterations in the brains of mice transgenic for the carboxy terminal portion of the amyloid precursor protein gene, Soc. Neurosci. Abstr., 18, 730
  23. Prickett, 1989, A calcium-dependent antibody for identification and purification of recombinant proteins, Biotechniques, 7, 580
  24. Quon, 1991, Formation of β-amyloid protein deposits in brains of transgenic mice, Nature, 352, 239, 10.1038/352239a0 · DOI
  25. Rye, 1993, The distribution of Alz-50 immunoreactivity in the normal human brain, Neuroscience, 56, 109, 10.1016/0306-4522(93)90567-Y · DOI
  26. Snow, 1994, An important role of heparan sulfate proteoglycan (perlecan) in a model system for the deposition and persistence of fibrillar AR-amyloid in rat brain, Neuron, 12, 219, 10.1016/0896-6273(94)90165-1 · DOI
  27. Suzuki, 1994, An increased percentage of long amyloid protein secreted by familial amyloid protein precursor (APP717) mutants, Science, 264, 1336, 10.1126/science.8191290 · DOI · Paper page
  28. Terry, 1991, Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment, Ann. Neurol., 30, 572, 10.1002/ana.410300410 · DOI · Paper page
  29. van de Nes, 1994, The monoclonal antibody Alz-50, used to reveal cytoskeletal changes in Alzheimer's disease, also reacts with a large subpopulation of somatostatin neurons in the normal human hypothalamus and adjoining areas, Brain Res., 655, 97, 10.1016/0006-8993(94)91602-0 · DOI
  30. Wolf, 1990, Identification and characterization of C-terminal fragments of the β-amyloid precursor produced in cell culture, EMBO J., 9, 2079, 10.1002/j.1460-2075.1990.tb07375.x · DOI
  31. Wolozin, 1986, A neuronal antigen in the brains of Alzheimer patients, Science, 232, 8, 10.1126/science.3083509 · DOI
  32. Yankner, 1989, Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease, Science, 245, 417, 10.1126/science.2474201 · DOI · Paper page
  33. Yoshikawa, 1992, Degeneration in vitro of postmitotic neurons overexpressing the Alzheimer amyloid protein precursor, Nature, 359, 64, 10.1038/359064a0 · DOI

Cited by

Sorted by citations

Metadata

Authors
Neve, R. L., Boyce, F. M., McPhie, D. L., Greenan, J., & Oster-Granite, M. L.
Venue
Neurobiology of Aging
Publisher
Elsevier BV
Published
1996-03
Volume
17
Issue
2
Pages
191-203
ISSN
0197-4580
DOI
10.1016/0197-4580(95)02074-8
Cited by
46
References
2
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review